Patritumab (Anti-ERBB3 / HER3)
Product Specifications
CAS Number
1262787-83-6
Synonyms
Human Anti-ERBB3 Recombinant Antibody
Target
HER2
Applications
Protein Tyrosine Kinase
Additionnal Information
Patritumab (Anti-ERBB3 / HER3) is a neutralizing monoclonal antibody targeting ERBB3. Patritumab shows a synergy with Cetuximab, potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors. MW: 145.5 KD.
Storage Conditions
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC470218-100 1x 100 µL
CD100 (Semaphorin-4D) (A8), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC940257-100 1x 100 µL
Cytokeratin, HMW (AE-3), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040003-500 1x 500 µL
CD45RO (UCHL-1), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 